Healthcare Finance News May 12, 2022
Jeff Lagasse

The proposed transaction includes Pfizer’s acquisition of Biohaven’s migraine drugs, including rimegepant and zavegepant.

Drug manufacturer Pfizer has entered into a definitive agreement to acquire Biohaven Pharmaceuticals, a maker of migraine treatments, for $11.6 billion, the former said this week.

Pfizer will also make payments at closing to settle Biohaven’s third party debt and for the redemption of all outstanding shares of Biohaven’s redeemable preferred stock.

The boards of directors of both Biohaven and Pfizer have unanimously approved the transaction.

The proposed transaction includes Pfizer’s acquisition of Biohaven’s migraine drugs, including rimegepant, which is approved in the U.S. under the name NURTEC ODT. The same drug is approved in the European Union under the trade name VYDURA.

Also included in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
AstraZeneca plans independent drug supply chains for US and China, CEO says
Digital Platforms Streamline Medication Access and Delivery
Pharma Pulse 3/27/24: Patients Hate ‘Forever’ Drugs—Is Wegovy Different? Low Melatonin Can Increase Risk of Neurological Disorders & more
Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Share This Article